Aspen Pharmacare Holdings Limited (JSE: APN)

Market Cap	77.20B
Revenue (ttm)	44.71B
Net Income (ttm)	4.40B
Shares Out	444.21M
EPS (ttm)	9.91
PE Ratio	17.53
Forward PE	10.23
Dividend	3.59 (2.07%)
Ex-Dividend Date	Sep 18, 2024

Volume	4,969,071
Open	16,775
Previous Close	16,547
Day's Range	16,578 - 17,680
52-Week Range	16,310 - 25,296
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 3, 2024

About Aspen Pharmacare Holdings

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general, local, and regional anesthetic; low molecular weight heparin; regional and spinal anesthetic; and opioid analegesic under the Diprivan, Emla, Fraxiparine, Marcaine, Ultiva, and Xylocaine brand names. It also offers such as sleeping aid, thyroid hormone, immunosuppressant, iron supplement, analgesic ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1850
• Employees: 9,350
• Stock Exchange: Johannesburg Stock Exchange
• Ticker Symbol: APN

Financial Performance

In 2024, Aspen Pharmacare Holdings's revenue was 44.71 billion, an increase of 9.82% compared to the previous year's 40.71 billion. Earnings were 4.40 billion, a decrease of -15.76%.